Literature DB >> 15710597

Morbidity and non-relapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide: a retrospective comparison of oral versus intravenous busulfan.

So-Eun Kim, Je-Hwan Lee, Seong-Jun Choi, Jung-Hee Lee, Seong-Gil Ryu, Kyoo-Hyung Lee.   

Abstract

We retrospectively compared morbidity and non-relapse mortality (NRM) after allogeneic bone marrow transplantation (BMT) in 236 adults with leukemia and myelodysplastic syndrome conditioned with cyclophosphamide plus oral versus intravenous busulfan. Our findings demonstrate that conditioning therapy with intravenous busulfan resulted in lower morbidity and NRM than did oral busulfan.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15710597

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  8 in total

1.  Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide.

Authors:  Lindsey R Lombardi; Christopher G Kanakry; Marianna Zahurak; Nadira Durakovic; Javier Bolaños-Meade; Yvette L Kasamon; Douglas E Gladstone; William Matsui; Ivan Borrello; Carol Ann Huff; Lode J Swinnen; Robert A Brodsky; Richard F Ambinder; Ephraim J Fuchs; Gary L Rosner; Richard J Jones; Leo Luznik
Journal:  Leuk Lymphoma       Date:  2015-10-12

2.  Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine.

Authors:  Taku Kikuchi; Takehiko Mori; Chikako Ohwada; Masahiro Onoda; Hiroaki Shimizu; Hiroki Yokoyama; Makoto Onizuka; Yuya Koda; Jun Kato; Yusuke Takeda; Yutaro Hino; Tatsuzo Mishina; Emiko Sakaida; Katsuhiro Shono; Yuhei Nagao; Akira Yokota; Kana Matsumoto; Kunihiko Morita; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2020-09-04       Impact factor: 2.490

3.  Once-daily i.v. BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients.

Authors:  J Yin; Y Xiao; H Zheng; Y C Zhang
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

4.  Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning.

Authors:  Jeannine S McCune; Tao Wang; Khalid Bo-Subait; Mahmoud Aljurf; Amer Beitinjaneh; Joseph Bubalo; Jean-Yves Cahn; Jan Cerny; Saurabh Chhabra; Aaron Cumpston; L Lee Dupuis; Hillard M Lazarus; David I Marks; Richard T Maziarz; Maxim Norkin; Tim Prestidge; Shin Mineishi; Maxwell M Krem; Marcelo Pasquini; Paul J Martin
Journal:  Biol Blood Marrow Transplant       Date:  2019-03-11       Impact factor: 5.742

5.  Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.

Authors:  Borje S Andersson; Benigno C Valdez; Marcos de Lima; Xuemei Wang; Peter F Thall; Laura L Worth; Uday Popat; Timothy Madden; Chitra Hosing; Amin Alousi; Gabriela Rondon; Partow Kebriaei; Elizabeth J Shpall; Roy B Jones; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-11       Impact factor: 5.742

Review 6.  Busulfan in hematopoietic stem cell transplantation.

Authors:  Stefan O Ciurea; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2009-02-12       Impact factor: 5.742

7.  Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.

Authors:  Gheath Alatrash; Peter F Thall; Benigno C Valdez; Patricia S Fox; Jing Ning; Haven R Garber; Selma Janbey; Laura L Worth; Uday Popat; Chitra Hosing; Amin M Alousi; Partow Kebriaei; Elizabeth J Shpall; Roy B Jones; Marcos de Lima; Gabriela Rondon; Julianne Chen; Richard E Champlin; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2016-07-01       Impact factor: 5.742

8.  Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT.

Authors:  Karin Berger; Dorothee Schopohl; Christina Rieger; Helmut Ostermann
Journal:  Support Care Cancer       Date:  2015-03-17       Impact factor: 3.603
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.